Device Trial Radar · NCT05893797
A Study of LY8888AX in Participants Using a Connected Insulin Management Platform
Last checked: Nov 19, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Oct 5, 2023
Primary completion
Sep 16, 2024
Study completion Sep 16, 2024
Sponsor
- Lead sponsor
- Eli Lilly and CompanyNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 8, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess participant adherence and glucose control while using a connected insulin management platform. Approximately 50 participants will be enrolled in each country.
Conditions
- Type 1 Diabetes
- Type 2 Diabetes
- Type 2 Diabetes Treated With Insulin
Interventions
Insulin LisproDrug
As prescribed.
Tempo Smart ButtonDevice
Attached to the Tempo Pen
Dexcom G6 CGMDevice
Continuous glucose monitor
Glooko Research Mobile App (RMA)Device
Installed on a study provided android phone.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Missed Bolus Doses (MBDs) Per WeekTime frame: Study Period 1: Week 6 ; Study Period 2: Week 18
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
CHU de Besancon Hopital Jean Minjoz
Besançon, France
Centre Hospitalier Sud Francilien-Pharmacie
Corbeil-Essonnes, France
Chu de Grenoble
Grenoble Cédex 9, France
6 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.